CTIC Cti Biopharma Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTIC

Price (delayed)

$4.395

Market cap

$579.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$658.08M

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their ...

Highlights
CTIC's gross profit has surged by 65% since the previous quarter
The revenue has soared by 64% from the previous quarter
CTIC's quick ratio has plunged by 62% from the previous quarter but it is up by 19% YoY
Cti Biopharma's debt has surged by 130% YoY
The company's equity fell by 4.4% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ctibiopharma.com/
Peers: AMGN BMY TEVA BAX

Key stats

What are the main financial stats of CTIC
Market
Shares outstanding
131.84M
Market cap
$579.42M
Enterprise value
$658.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
9.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.2
Earnings
Revenue
$53.95M
EBIT
-$79.85M
EBITDA
-$77.9M
Free cash flow
-$81.19M
Per share
EPS
-$0.81
Free cash flow per share
-$0.71
Book value per share
-$0.14
Revenue per share
$0.47
TBVPS
$0.9
Balance sheet
Total assets
$125.93M
Total liabilities
$143.5M
Debt
$109.08M
Equity
-$17.58M
Working capital
$18.26M
Liquidity
Debt to equity
-6.21
Current ratio
1.23
Quick ratio
1.17
Net debt/EBITDA
-1.01
Margins
EBITDA margin
-144.4%
Gross margin
93.5%
Net margin
-172.4%
Operating margin
-147.9%
Efficiency
Return on assets
-72.2%
Return on equity
N/A
Return on invested capital
-83%
Return on capital employed
-178.3%
Return on sales
-148%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTIC stock price

How has the Cti Biopharma stock price performed over time
Intraday
-1.24%
1 week
-0.11%
1 month
-18.61%
1 year
1.74%
YTD
-26.87%
QTD
-26.87%

Financial performance

How have Cti Biopharma's revenue and profit performed over time
Revenue
$53.95M
Gross profit
$50.43M
Operating income
-$79.8M
Net income
-$92.99M
Gross margin
93.5%
Net margin
-172.4%
CTIC's gross profit has surged by 65% since the previous quarter
The revenue has soared by 64% from the previous quarter
The operating margin has soared by 52% QoQ
Cti Biopharma's net margin has increased by 50% QoQ

Growth

What is Cti Biopharma's growth rate over time

Valuation

What is Cti Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
9.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.2
The EPS is up by 26% since the previous quarter and by 26% year-on-year
The company's equity fell by 4.4% QoQ
The stock's price to sales (P/S) is 87% less than its last 4 quarters average of 70.4
The revenue has soared by 64% from the previous quarter

Efficiency

How efficient is Cti Biopharma business performance
The ROS has soared by 52% since the previous quarter
The company's return on assets rose by 46% YoY and by 26% QoQ
The return on invested capital rose by 44% since the previous quarter

Dividends

What is CTIC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTIC.

Financial health

How did Cti Biopharma financials performed over time
CTIC's total assets is 12% smaller than its total liabilities
The total liabilities has soared by 109% YoY and by 2.3% QoQ
CTIC's total assets has surged by 74% year-on-year
The debt to equity has dropped by 149% year-on-year but it rose by 3.3% since the previous quarter
Cti Biopharma's debt has surged by 130% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.